A new paper in A&D examines how semaglutide use relates to first-time Alzheimer's diagnoses in people with type 2 diabetes.
Recap by typeshit. Post by Alzheimer's & Dementia Journals on X.
Researchers are starting to explain the shifts in libido some GLP-1 users report. The full story covers what scientists have found so far.
Bikman says the added glucagon receptor push raises energy use and liver fat burning, and points to 24.2% weight loss on 12 mg in phase 2.
9:08
Archibald takes on a common question about low retatrutide doses and the drug's glucagon action. His view, not settled science, and retatrutide is still unapproved.
A report says an Eli Lilly drug helped protect muscle mass when combined with Novo's Wegovy, addressing a common worry about lean mass loss.
A Facebook user explains that compounded GLP-1 versions were allowed during the branded drug shortage and flags what that means for people still using them.
A thyroid problem pushed Victor's weight up and hurt his blood pressure and blood sugar. The story picks up with what his doctor did next.
Loading…